Q-omics provides the consensus-scored TNFSF11 profile across patient tissues and cancer cell-line models. TNFSF11 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, TNFSF11 is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, TNFSF11 RNA expression shows 13,768 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight OV, LUAD, and LSCC as cancer lineages where TNFSF11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFSF11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFSF11 survival associations across molecular data types. TNFSF11 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFSF11 RNA expression–survival associations across cancer types. High TNFSF11 expression shows unfavorable associations in OV, UVM, LUAD and CESC, but favorable associations in UCEC and SKCM. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for TNFSF11 RNA expression.
This table summarizes TNFSF11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TNFSF11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFSF11 shows higher tumor expression in LUAD, HNSC, KIRC, STAD, THCA and COAD. The LUAD box plot shows higher TNFSF11 RNA expression in tumor versus normal tissue (log2 FC = +1.469, t-test p < 0.001).
This table shows molecular features associated with TNFSF11 in patient tissues and cancer cell lines. In patient samples, TNFSF11 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFSF11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
